Argenx has agreed to acquire Forte Biosciences for $2.2 billion, a deal described across multiple outlets as aimed at expanding Argenx’s immunology and autoimmune drug pipeline. The Wall Street Journal reports the acquisition represents a 41% premium to Forte’s closing price on Friday. Several sources characterize the transaction as strengthening Argenx’s ability to pursue treatments for multiple autoimmune diseases, reflecting Forte’s technology and pipeline assets. Other coverage also notes that Forte shares rise following the announcement, indicating market reaction to the proposed terms.
Yahoo Finance and other outlets highlight the potential strategic fit between Argenx’s focus and Forte’s development programs, including a reference to Forte’s FB102 asset in some reporting. Across the articles, the key common elements are the overall price of $2.2 billion, Forte’s premium relative to its prior closing value, and the stated goal of bolstering Argenx’s future pipeline in immunology and autoimmune conditions. Details on deal timing and regulatory steps are not specified in the provided excerpts.
